Written Question·Department of Health and Social Care·UIN 105469

Blood Cancer: Medical Treatments

Tabled: 13 January 2026

Answered: 20 January 2026

Question

Paul Davies

To ask the Secretary of State for Health and Social Care, if he will take steps to ensure NHS patients with Mantle Cell Lymphoma will continue to be able to receive the CAR-T treatment Tecartus after it has exited the Cancer Drugs Fund.

Answer

Dr Zubir Ahmed

Decisions on whether new medicines should be routinely funded by the National Health Service in England are made by the National Institute for Health and Care Excellence (NICE) on the basis of an evaluation of their costs and benefits. NICE is currently r...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 105469) →